• Oruka Therapeutics SVP, Finance Arjun Agarwal reported option exercises on May 18, 2026, acquiring 7,833 common shares at prices of USD 12.5 to USD 34.39.
• He also reported selling 10,290 common shares the same day at weighted average prices of USD 58.34 to USD 61.16.
• Beneficial ownership stood at 16,406 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000907654-26-000041), on May 18, 2026, and is solely responsible for the information contained therein.